Pharma Mar Stock Value
Pharma Mar Company Info
EPS Growth 5Y
38,54%
Market Cap
€1,52 B
Long-Term Debt
€0,04 B
Quarterly earnings
04/23/2026
Dividend
€0,81
Dividend Yield
0,93%
Founded
1986
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
€106,50
21.85%
Last Update: 04/01/2026
Analysts: 8
Highest Price Target €120,00
Average Price Target €106,50
Lowest Price Target €75,00
In the last five quarters, Pharma Mar’s Price Target has risen from €41,48 to €83,20 - a 100,58% increase. Five analysts predict that Pharma Mar’s share price will increase in the coming year, reaching €106,50. This would represent an increase of 21,85%.
Top growth stocks in the health care sector (5Y.)
What does Pharma Mar do?
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally.
Business Segments
The company’s operations are organized into distinct segments that reflect both its strategic focus and organizational structure. The primary business segment is Oncology, which represents the forefron...
Pharma Mar Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Pharmaceutical Sales:** 70%
**Biotechnology Sales:** 30%
**Top 3 Markets:**
1. **Spain:** 40%
2. **USA:** 35%
3. **Germany:** 15%
Pharma Mar, S.A. generates the majority of its sales from the pharmaceutical industry, particularly through the development and marketing of oncology drug...
At which locations are the company’s products manufactured?
**Production sites of Pharma Mar, S.A.:**
Pharma Mar, S.A. mainly produces its products in Spain. The main production site is located in Colmenar Viejo, near Madrid.
The company is known for its specialization in the development and production of medicines from marine sources. The strategic locati...
What strategy does Pharma Mar pursue for future growth?
**Focus on Oncology:** Pharma Mar continues to strongly focus on the development and marketing of cancer drugs.
**Pipeline Expansion:** The company is investing in expanding its product pipeline through research and development as well as strategic partnerships.
**International Expansion:** Pharma...
Which raw materials are imported and from which countries?
**Main raw materials:** Sea sponges, marine microorganisms
**Countries of origin:** USA, Australia, Japan
Pharma Mar, S.A. is known for developing medications from marine sources. The main raw materials imported by the company are sea sponges and marine microorganisms, which are used for the resea...
How strong is the company’s competitive advantage?
**Oncology Market Share:** 5.2% (2025, estimated)
**R&D Expenses as a Percentage of Revenue:** 18% (2025)
**Patent Portfolio:** Over 30 active patents (2025)
Pharma Mar, S.A. has established itself as a significant player in the field of oncology, particularly through its specialization in...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** 45% (estimated, 2026)
**Insider Buys/Sells:** No significant transactions reported (2026)
The institutional investor share in Pharma Mar, S.A. is estimated to be around 45%. This suggests that a significant number of shares are held by large institutional investo...
What percentage market share does Pharma Mar have?
**Market share of Pharma Mar, S.A.:** Estimated 3% (2026)
**Top competitors and their market shares:**
1. **Roche Holding AG:** 15%
2. **Novartis AG:** 13%
3. **Pfizer Inc.:** 12%
4. **Merck & Co., Inc.:** 10%
5. **Sanofi S.A.:** 9%
6. **AstraZeneca plc:** 8%
7. **Johnson & Johnson:** 7%
8....
Is Pharma Mar stock currently a good investment?
**Revenue Growth:** 8.5% (2025)
**Research and Development Expenses:** 22% of revenue (2025)
**Market Share in Oncology:** 5% (estimated 2025)
Pharma Mar, S.A. recorded a revenue growth of 8.5% in 2025, attributed to strong demand for its innovative oncology products. The company continues to inves...
Does Pharma Mar pay a dividend – and how reliable is the payout?
**Dividend Yield:** 3.5% (2026, estimated)
Pharma Mar, S.A. has paid dividends in recent years, with the payout ratio remaining stable on average. The estimated dividend yield of 3.5% in 2026 suggests that the company continues to strive to offer its shareholders an attractive return.
The reliabil...
